1k
900
))
Is there a way to treat liver metastasis secondary to uveal melanoma without introducing systemic, treatment-related toxicity? Dr. Altan Ahmed (interventional radiologist at Moffitt Cancer Center) and Dr. Sid Padia (interventional radiologist at UCLA) join guest-host Dr. Kavi Krishnasamy to discuss HEPZATO, a novel device-based treatment for liver metastases from uveal melanoma.
---
This podcast is supported by:
RADPAD® Radiation Protection
https://www.radpad.com/
---
SYNPOSIS
Dr. Ahmed and Dr. Padia begin by exploring the design and setup of the HEPZATO clinical trials, while also speaking on patient selection criteria. The doctors then talk through the technical aspects of the intervention. After covering workflow and considerations related to procedure timing and coordination, the doctors go on to discuss drug dosing and optimizing treatment cycles. The episode concludes with current gaps in literature, current and future research aims, and potential future applications of the HEPZATO modality in treating other malignancies such as colorectal cancer.
---
TIMESTAMPS
00:00 - Introduction
05:40 - Patient Selection Criteria
09:49 - Workflow
19:17 - Procedure Timing and Coordination
29:39 - Challenges and Considerations in Drug Dosing
32:39 - Optimizing Treatment Cycles and Patient Response
37:56 - Managing Post-Treatment and Adverse Effects
43:43 - Future Research and Gaps in Current Interventions
50:45 - Exploring New Applications for PHP Therapy
55:02 - Conclusion
---
RESOURCES
Hepzato:
https://hepzatokit.com/
FOCUS Trial - Efficacy and Safety of the Melphalan/Hepatic Delivery System in Patients with Unresectable Metastatic Uveal Melanoma: Results from an Open-Label, Single-Arm, Multicenter Phase 3 Study:
https://pubmed.ncbi.nlm.nih.gov/38704501/
FOCUS phase 3 trial results: Percutaneous hepatic perfusion (PHP) with melphalan for patients with ocular melanoma liver metastases (PHP-OCM-301/301A):
https://ascopubs.org/doi/pdf/10.1200/JCO.2022.40.16_suppl.9510
Combining Melphalan Percutaneous Hepatic Perfusion with Ipilimumab Plus Nivolumab in Advanced Uveal Melanoma: First Safety and Efficacy Data from the Phase Ib Part of the Chopin Trial:
https://pubmed.ncbi.nlm.nih.gov/36624292/
Troponin Elevation in Patients Undergoing Percutaneous Hepatic Perfusion for Metastatic Uveal Melanoma:
https://pmc.ncbi.nlm.nih.gov/articles/PMC11010739/
Percutaneous Hepatic Perfusion with Melphalan in Patients with Unresectable Ocular Melanoma Metastases Confined to the Liver: A Prospective Phase II Study:
https://pmc.ncbi.nlm.nih.gov/articles/PMC7801354/
Southampton group - Quality of life after melphalan percutaneous hepatic perfusion for patients with metastatic uveal melanoma:
https://pmc.ncbi.nlm.nih.gov/articles/PMC10906212/
Leiden group - Quality of Life Analysis of Patients Treated with Percutaneous Hepatic Perfusion for Uveal Melanoma Liver Metastases:
https://pubmed.ncbi.nlm.nih.gov/38587534/
550 episodes
Is there a way to treat liver metastasis secondary to uveal melanoma without introducing systemic, treatment-related toxicity? Dr. Altan Ahmed (interventional radiologist at Moffitt Cancer Center) and Dr. Sid Padia (interventional radiologist at UCLA) join guest-host Dr. Kavi Krishnasamy to discuss HEPZATO, a novel device-based treatment for liver metastases from uveal melanoma.
---
This podcast is supported by:
RADPAD® Radiation Protection
https://www.radpad.com/
---
SYNPOSIS
Dr. Ahmed and Dr. Padia begin by exploring the design and setup of the HEPZATO clinical trials, while also speaking on patient selection criteria. The doctors then talk through the technical aspects of the intervention. After covering workflow and considerations related to procedure timing and coordination, the doctors go on to discuss drug dosing and optimizing treatment cycles. The episode concludes with current gaps in literature, current and future research aims, and potential future applications of the HEPZATO modality in treating other malignancies such as colorectal cancer.
---
TIMESTAMPS
00:00 - Introduction
05:40 - Patient Selection Criteria
09:49 - Workflow
19:17 - Procedure Timing and Coordination
29:39 - Challenges and Considerations in Drug Dosing
32:39 - Optimizing Treatment Cycles and Patient Response
37:56 - Managing Post-Treatment and Adverse Effects
43:43 - Future Research and Gaps in Current Interventions
50:45 - Exploring New Applications for PHP Therapy
55:02 - Conclusion
---
RESOURCES
Hepzato:
https://hepzatokit.com/
FOCUS Trial - Efficacy and Safety of the Melphalan/Hepatic Delivery System in Patients with Unresectable Metastatic Uveal Melanoma: Results from an Open-Label, Single-Arm, Multicenter Phase 3 Study:
https://pubmed.ncbi.nlm.nih.gov/38704501/
FOCUS phase 3 trial results: Percutaneous hepatic perfusion (PHP) with melphalan for patients with ocular melanoma liver metastases (PHP-OCM-301/301A):
https://ascopubs.org/doi/pdf/10.1200/JCO.2022.40.16_suppl.9510
Combining Melphalan Percutaneous Hepatic Perfusion with Ipilimumab Plus Nivolumab in Advanced Uveal Melanoma: First Safety and Efficacy Data from the Phase Ib Part of the Chopin Trial:
https://pubmed.ncbi.nlm.nih.gov/36624292/
Troponin Elevation in Patients Undergoing Percutaneous Hepatic Perfusion for Metastatic Uveal Melanoma:
https://pmc.ncbi.nlm.nih.gov/articles/PMC11010739/
Percutaneous Hepatic Perfusion with Melphalan in Patients with Unresectable Ocular Melanoma Metastases Confined to the Liver: A Prospective Phase II Study:
https://pmc.ncbi.nlm.nih.gov/articles/PMC7801354/
Southampton group - Quality of life after melphalan percutaneous hepatic perfusion for patients with metastatic uveal melanoma:
https://pmc.ncbi.nlm.nih.gov/articles/PMC10906212/
Leiden group - Quality of Life Analysis of Patients Treated with Percutaneous Hepatic Perfusion for Uveal Melanoma Liver Metastases:
https://pubmed.ncbi.nlm.nih.gov/38587534/
550 episodes
Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.
1k900
Share
